1 / 44

DEVELOPMENT AND UTLILITY OF DIRECT ALCOHOL BIOMARKERS

UNITED STATES DRUG TESTING LABORATORIES, INC. DEVELOPMENT AND UTLILITY OF DIRECT ALCOHOL BIOMARKERS. CHARLES A. PLATE, Ph.D. LABORATORY DIRECTOR. Testing Innovation Research Development. PROPERTIES OF SELECTED INDIRECT ALCOHOL BIOMARKERS.

fai
Download Presentation

DEVELOPMENT AND UTLILITY OF DIRECT ALCOHOL BIOMARKERS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. UNITED STATES DRUG TESTING LABORATORIES, INC. DEVELOPMENT AND UTLILITY OF DIRECT ALCOHOL BIOMARKERS CHARLES A. PLATE, Ph.D. LABORATORY DIRECTOR Testing Innovation Research Development

  2. PROPERTIES OF SELECTED INDIRECT ALCOHOL BIOMARKERS Testing Innovation Research Development

  3. PROPERTIES OF DIRECT ALCOHOL BIOMARKERS Testing Innovation Research Development

  4. STRUCTURE OF ETHYL GLUCURONIDE Testing Innovation Research Development

  5. STRUCTURE OF ETHYL SULFATE Testing Innovation Research Development

  6. SYNTHESIS OF ETHYL GLUCURONIDE AND ETHYL SULFATE UDP-GLUCURONYL GLUCURONATE + EtOH ETHYL GLUCURONATE TRANSFERASE SULFOTRANSFERASE SULFATE + EtOH ETHYL SULFATE Testing Innovation Research Development

  7. EtG / EtS IN URINE • Confirms alcohol exposure for up to 5 days following consumption. • -Glucuronidase from urinary tract infections destroys EtG but not EtS. • Cut-offs are variable and can be set to meet client’s needs. • Innocent-positives can be generated by alcohol-containing hand sanitizers and mouthwashes. Testing Innovation Research Development

  8. EtG ANALYSIS EtG Cal 500 ng/ml Testing Innovation Research Development

  9. EtS ANALYSIS EtS Cal 125 ng/ml 125.0/80.0 Testing Innovation Research Development

  10. EtG / EtS IN URINE • Positive EtG/EtS is NOT unequivocal evidence of beverage alcohol consumption. • Positive EtG/EtS requires further examination, either clinically or by using a biomarker assay with a higher exposure threshold for positivity. Testing Innovation Research Development

  11. USE OF EtG / EtS IN URINE • Determination of alcohol ingestion • Window of measure = 1 - 5 days • Indicates that alcohol has been consumed • Primarily used for monitoring in enforced abstinence programs (impaired professionals) Testing Innovation Research Development

  12. STRUCTURE OF PHOSPHATIDYLETHANOL Testing Innovation Research Development

  13. SYNTHESIS OF PHOSPHATIDYLETHANOL PHOSPHOLIPASE D PHOSPHATIDYLCHOLINE + EtOH PHOSPHATIDYLETHANOL Testing Innovation Research Development

  14. PHOSPHATIDYLETHANOL IN BLOOD • A direct alcohol biomarker that incorporates into cell membranes • Long half-life--not metabolized • Remains in red cell membrane for the life of the blood cell or spontaneous hydrolysis - 3 weeks • Can be detected following ingestion of 200 grams of ethanol over 1 week • Window of detection 3 weeks or longer Testing Innovation Research Development

  15. PHOSPHATIDYLETHANOL ANALYSIS 701.3/255.0 701.3/281.0 Testing Innovation Research Development

  16. USE OF PHOSPHATIDYLETHANOL IN BLOOD • Determination of longer term alcohol abuse • Window of measure up to 3 weeks • Indicates heavy drinking over 3 week period • Identifies potential problem drinkers • Could be used to screen transplant recipients Testing Innovation Research Development

  17. FATTY ACID ETHYL ESTER STRUCTURE OF ETHYL OLEATE Testing Innovation Research Development

  18. SYNTHESIS OF FATTY ACID ETHYL ESTERS (FAEE’s) LONG CHAIN ACYL-CoA:ETHANOL FATTY ACIDS + EtOH FATTY ACID ETHYL ESTERS O-ACYLTRANSFERASE Testing Innovation Research Development

  19. FAEE’s IN MECONIUM • Meconium is earliest stool of newborn containing intestinal epithelial cells, mucus, lanugo, amniotic fluid, bile, and water; tar-like, sterile and odorless • FAEE’s present in meconium of infants delivered from known alcoholics • Detection of FAEE’s in meconium currently “gold standard” method of identifying infants exposed to alcohol in utero Testing Innovation Research Development

  20. FAEE ANALYSIS • FAEE’s are isolated from meconium using a solid-phase extraction technique • FAEE’s are analyzed using positive ion (PCI) chemical ionization gas chromatography / mass spectrometry (GC/MS) Testing Innovation Research Development

  21. Palmitate (C16:0) Palmitoleate (C16:1) Stearate (C18:0) Oleate (C18:1) Linoleate (C18:2) Linolenate (C18:3) Arachidonate (C20:4) CURRENT FAEE PROFILE Testing Innovation Research Development

  22. FAEE’S IDENTIFY A POTENTIAL HIGH RISK NEWBORN POPULATION Testing Innovation Research Development

  23. USE OF FAEE’s IN MECONIUM • Determination of fetal alcohol exposure in utero • Measure FAEE in fetal meconium • Window of measure > 20 weeks • Indicates alcohol usage during last half of pregnancy • Used by neonatologists when fetal alcohol exposure suspected Testing Innovation Research Development

  24. FUTURE POTENTIAL APPLICATIONS FOR EtG, FAEE’s, AND PHOSPHATIDYLETHANOL AS DIRECT ALCOHOL BIOMARKERS Testing Innovation Research Development

  25. FAEE IN HAIR • Potential biomarker for long-term alcohol abuse (up to 3 months) • Control group: <1 drink daily • Patient group: 11 + drinks daily • Hair specimens collected with interview • 1.5 inches in length • 100 mg in mass • Obtained Timeline Followback for 90 days Testing Innovation Research Development

  26. FAEE’s MEASURED • FAEE’s separated and detected by GC/MS • Ethyl myristate (E14:0) • Ethyl palmitate (E16:0) • Ethyl palmitoleate (E16:1) • Ethyl stearate (E18:0) • Ethyl oleate (E18:1) Testing Innovation Research Development

  27. FAEE IN HAIR Testing Innovation Research Development

  28. FAEE IN HAIR Group N *Alcohol Sensitivity Specificity (drinks/day) (%) (%) 25 11 ± 10 Patients 60 100 Female 6 17 ± 19 83 100 53 100 Male 19 9 ± 5 Testing Innovation Research Development

  29. CONCLUSIONS OF FAEE IN HAIR STUDY • Hair FAEE’s very specific biomarkers of long term alcohol abuse • Sensitivity of hair FAEE’s (60%) is not sufficiently sensitive as an assay to identify individuals with a history of long term alcohol abuse Testing Innovation Research Development

  30. EtG IN HAIR • Control group: teetotalers • Patient group: individuals in alcohol abuse programs • Hair specimens collected with interview • 1.5 inches in length • 100 mg in mass • Obtained Timeline Followback for 90 days Testing Innovation Research Development

  31. EtG IN HAIR ANALYSIS • Hair specimens washed sequentially with hexane, methylene chloride, and methanol • Hair specimens extracted with water • EtG partially purified from water extracts by solid phase extraction • EtG resolved from water residue and identified using LC/MS/MS Testing Innovation Research Development

  32. HAIR EtG IN CONTROLS AND PATIENTS Testing Innovation Research Development

  33. COMPARISON OF FAEE’s AND EtG IN HAIR AS ALCOHOL BIOMARKERS Testing Innovation Research Development

  34. PATIENTS TESTING NEGATIVE FOR HAIR FAEE’s BUT POSITIVE FOR HAIR EtG Testing Innovation Research Development

  35. CONCLUSIONS OF EtG IN HAIR STUDY • Hair EtG very specific biomarker of long term alcohol abuse • Sensitivity of hair EtG (80%) is better than any long term marker of alcohol abuse currently available • Our Phase I study • establishes feasibility of hair EtG as a long term alcohol biomarker • paves the way for a Phase II study to expand and diversify the drinking population studied and validate a hair EtG production test Testing Innovation Research Development

  36. PHOSPHATIDYLETHANOL • Alcohol biomarker in umbilical cord tissue • Alcohol biomarker in newborn blood spots • Two research studies sponsored by Phase I SBIR grants from NIH/NIAAA Testing Innovation Research Development

  37. PHOSPHATIDYLETHANOL IN UMBILICAL CORD TISSUE • Virtues of umbilical cord tissue as opposed to meconium in drug/alcohol testing of newborns • Easier and more dependable collection • Greater sensitivity for certain drugs • Availability of umbilical cord from all babies while 8- 20% of newborns lack a meconium sample due to fetal stress Testing Innovation Research Development

  38. PHOSPHATIDYLETHANOL IN UMBILICAL CORD TISSUE • FAEE’s are the direct alcohol biomarker found in meconium; phosphatidylethanol not detected in meconium • Phosphatidylethanol is the direct alcohol biomarker found in umbilical cord tissue; FAEE’s present in umbilical cord tissue, but in very low amounts Testing Innovation Research Development

  39. PHOSPHATIDYLETHANOL IN NEWBORN BLOOD SPOTS • Newborns at high risk for fetal alcohol effects (FAE) • Approximately 126,000 born in 2006 • Costs for medical, surgical, behavioral, custodial, and judicial services for FAE children estimated to range between $75 million and $9.7 billion in 2000 • Current “gold standard” alcohol biomarker test to aid in identifying these high risk babies has a sensitivity of 68% Testing Innovation Research Development

  40. Previous maternal history of drug/alcohol abuse Maternal self-report of drug/alcohol usage during current pregnancy No prenatal care No permanent address Presence of sexually transmitted disease(s) Mother or father appear intoxicated, “high”, abusive, or exhibiting inappropriate behavior CRITERIA THAT INITIATES TESTING OF NEWBORNS FOR ALCOHOL OR DRUGS OF ABUSE EXPOSURE Testing Innovation Research Development

  41. DO THESE CRITERIA WORK IN IDENTIFYING DRUG/ALCOHOL EXPOSED NEWBORNS? • In the case of drugs of abuse YES • Incidence of exposure in sequential births 10% or less • Incidence when one or more criteria apply 35% or greater • In the case of alcohol exposure NO • Incidence of exposure in sequential births 14-18% • Incidence when one or more criteria apply 14-18% Testing Innovation Research Development

  42. PHOSPHATIDYLETHANOL IN NEWBORN BLOOD SPOTS • Potential screening test for detecting FAE newborns with high sensitivity and specificity • Phase I NIAAA SBIR grant to determine the feasibility of this test was recently awarded Testing Innovation Research Development

  43. USDTL RESEARCH FUNDING • NIH SBIR Grants from • National Institute of Drug Abuse • National Institute on Alcohol Abuse and Alcoholism Testing Innovation Research Development

  44. QUESTIONS? Testing Innovation Research Development

More Related